The dynamics of the main economic indicators for 2018 shows the profitable work of the FSUE Moscow Endocrine Plant. The Enterprise effectively uses its own assets, has a high share of fixed assets in the total value of assets, amounting to 45%, from which the amount of capital investment sent to increase of the value of fixed assets is 84%. As of January 1, 2019, the cost of fixed assets used in the production process increased by 112 million roubles and amounts to 440 million roubles of their residual cost.
The net assets of the Enterprise are 13 times higher than the authorized capital, which positively characterizes the financial situation, fully satisfying the requirements of normative acts imposed on the value of these indicators. Excess of net assets over authorized capital and at the same time their increase in 2018 by 4.3% indicates a good financial position of the enterprise. The growth of the balance sheet currency amounted to 12.5%.
The current (total) liquidity ratio and the quick liquidity ratio of the balance sheet show values by 2.35 times higher than the norm, this means that the enterprise has enough assets that can be converted into cash in a short time and repay short-term payables.
From 2015 to 2018, there has been a significant increase in revenue, from 2,499 million roubles to 3,728 million roubles. Such indicators as retained earnings, return on net assets, return on equity also increased, which generally indicates that the enterprise effectively uses non-current and current assets for receiving of profit. According to the results of work for 2018 net profit amounted to 103.6%. from the plan established by the production program. During the year deductions to the federal budget from net profit amounted to 31.8 million roubles, taxes and contributions for insurance premiums were paid in the amount of 511 million roubles.
There was an increase in the efficiency of use of labour resources at the enterprise - labour productivity increased by 14%, which ensures an increase in production volumes.
During the year the enterprise created a branch system for management of the promotion of scientifically-oriented activities from the production of subsidizing materials to the manufacture of drugs on their basis, their integration with the pharmaceutical development management of the parent organization was ensured. In total, the amount of development costs amounted to 244 million roubles from which 121 million roubles - from own resources.
The Enterprise has a high level of financial and payable stability, provides liquidity of balance, all current and subsequent liabilities, has sufficient working capital funds to repay short-term liabilities. It follows the path of innovative development, the improvement of quality and competitiveness of products. It masters new directions of activity, attracting for this purpose the funds of budget investments, bank loans, using its own earned funds.
Comment type is not specified in the component properties.